First Trade Date for MedImmune, Inc.
| Company Name | First Trade Date (yyyy-mm-dd) |
| MedImmune, Inc. | 1991-05-08 |
| Company Name | Symbol |
| MedImmune, Inc. | MEDI |
| History and Business of Company (this information may include date of incorporation) | |
|
MedImmune, Inc. (MEDI) focuses on developing and marketing products for infectious diseases and transplantation medicine. Since the start of operations in 1988, the company has sought to establish an initial commercial base using proven technologies and targeting well-understood diseases to support longer-term product development. This strategy has relied on the advancement of an internally developed pipeline of product candidates and in- licensing products from third parties. In September 1998, MEDI began marketing Synagis, a humanized monoclonal antibody effective in neutralizing respiratory syncytial virus (RSV), the most common cause of pneumonia and bronchiolitis in infants and toddlers. In 2000, the company sold $427 million of Synagis, up from $293 million in 1999. In general, MEDI expects most of its Synagis sales to occur in the fourth and first quarters of the year because of the seasonality of RSV in the United States. Another important product is CytoGam, an intravenous immune globulin enriched in antibodies against cytomegalovirus (CMV). This product is marketed in the U.S. for the attenuation of primary CMV disease associated with transplantation of the kidney, lung, liver, pancreas and heart. CMV is a major cause of illness and death in patients with weakened immune systems associated with organ transplantation or immunosuppressive diseases such as AIDS. Products in the R&D pipeline include vaccines for human papillomaviruses (HPVs) and MEDI-507 for graft-versus-host disease and certain autoimmune disorders. The company has begun dosing patients in its European Phase II study, the second in a series of Phase II studies for MEDI-507 expected to be conducted in 2001. In November 1999, MEDI completed the acquisition of U.S. Bioscience, Inc., a pharmaceutical company focused on developing and marketing products for infectious diseases, transplantation medicine, autoimmune disorders and cancer. U.S. Bioscience's shareholders received 0.15 Common shares of MEDI for each U.S. Bioscience share. April 19, 2001, MEDI and Genaera Corp. announced they had entered into a research collaboration and a worldwide exclusive licensing agreement to develop and commercialize antibodies or recombinant molecules against IL-9 to prevent symptoms of asthma and other respiratory diseases. As part of the research agreement, the companies will collaborate on the creation of specific assays and respiratory disease models for use in assessing product candidates developed by MEDI. INCORPORATED in Delaware June 29, 1987 as Molecular Vaccines Inc.; present title adopted Oct. 2, 1990. OFFICE- 35 West Watkins Mill Road, Gaithersburg, MD 20878 (Tel.: 301-417-0770). Fax - 301-527- 4207. WEBSITE-http://www.medimmune.com. | |
IMPORTANT DISCLAIMER: By reading any of the material on this website you agree to our DISCLAIMER: The Magi Society, Magi Astrologers Worldwide Corporation make no claims whatsoever concerning the validity of the information provided herein, and will not be held liable for any use thereof. No information or opinion expressed here is a solicitation to buy or sell securities, bonds, real estate, commodities, options, futures or any financial instruments whatsoever.
Back to first trade date main page
Back to financial astrology page
© 1999-2004 by Magi Astrologers Worldwide Corporation. All Rights Reserved.